Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: Results through Week 24 of the Phase 3b, randomised, double-blind, placebo-controlled APEX study
Ann Rheum Dis 2025;0:1−12 Doi: 10.1016/j.ard.2025.08.006
Mease et al. showed that guselkumab provided significantly higher rates of clinical improvement and significant inhibition of structural damage progression versus PBO, with no new safety signals, at Week 24 in biologic-naïve participants with active and erosive PsA. Mease et al. report primary efficacy and safety results for the double-blind PBO-controlled phase (Weeks 0-24) of the 3-year APEX study.
The findings from the APEX study not only confirm the highly favourable benefit-risk profile of guselkumab Q4W and Q8W in treating the signs and symptoms of active PsA across a broad range of patient types but also support guselkumab as the only IL-23p19-subunit inhibitor to demonstrate statistically significant inhibition of radiographic progression in this population. Guselkumab is unique in its ability to comprehensively address important treatment goals, including preservation of joint health, shared by patients with PsA and their health care providers.
Keywords:
